Business context and reporting period
The supplied filing is SMSA Ballinger Acquisition Corp.’s Form 10-K for the fiscal year ended December 31, 2014; it does not identify REALLOYS INC. The filing describes SMSA as a development-stage shell company pursuing a plan to market nasal aspirators and other healthcare consumer products in South America, initially Brazil and Chile. It had not purchased inventory, generated revenue, or established sales or distribution arrangements by year-end.
Financial results and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $24,152 | $12,291 |
| Net loss | $23,212 | $12,291 |
| Cash from operations | $(28,152) | $(5,851) |
| Cash at year-end | $119 | $9,500 |
| Total assets | $119 | $9,500 |
| Total liabilities | $1,500 | $6,440 |
| Working capital / stockholders’ equity (deficit) | $(1,381) | $3,060 |
Professional fees were $22,898 in 2014 versus $10,692 in 2013; other general and administrative expense was $1,254 versus $1,599. Other income of $940 reduced the 2014 net loss from the $24,152 operating loss. No income tax expense, interest paid, or investing cash flow was reported. The filing reports no operating assets; it does not disclose interest-bearing debt. Gross or operating margins are not meaningful because there were no sales.
Material changes versus 2013
- Net loss increased by $10,921 as total expenses nearly doubled, primarily due to higher professional fees.
- Operating cash outflow increased to $28,152 from $5,851, while year-end cash fell to $119 from $9,500.
- Working capital moved from positive $3,060 to a deficit of $1,381. HFG and/or HFI contributed $18,771 in 2014 to support operations, recorded as additional paid-in capital; the comparable contribution was $5,851.
Outlook, risks, and unusual items
- Management estimated it needed up to $50,000 over the next 12 months for corporate costs and initial market research, and at least $500,000 to establish a viable distribution system. Neither the majority stockholder nor Snotarator LLC is obligated to provide funding. The auditor cited substantial doubt about the company’s ability to continue as a going concern.
- Management expected market research in Brazil and Chile to continue through the end of Q2 2015, aimed to complete a $500,000 financing by August 31, 2015, and projected full distribution-system implementation by December 31, 2015. These are plans, not assured outcomes; distribution depends on successful financing and favorable market feedback.
- The exclusive Snotarator distribution agreement covers South America and currently concerns two nasal aspirator products. The filing gives inconsistent expiration dates: May 15, 2015 in some sections and May 31, 2015 in another. Extension requires both parties’ written consent. The company had no product orders or inventory at year-end.
- Orsolya Peresztegi, the sole officer and director, owns 94.7% of outstanding shares and also manages and co-owns Snotarator LLC. The filing notes potential conflicts over her time and related-party relationships. HFG Consulting, an affiliate of HFG/HFI, agreed to provide marketing assistance without consideration.
- The company warned that future financing could substantially dilute existing holders or include preferred securities with senior rights. It has no established public trading market. Disclosure controls and internal control over financial reporting were reported ineffective, citing one person holding the CEO/CFO roles, lack of segregation of duties, and no separate audit committee.
Important facts for investors to verify
- Confirm the issuer’s identity: the provided filing is for SMSA Ballinger Acquisition Corp., not REALLOYS INC.
- Review the audited statements and going-concern disclosures, including the $119 cash balance, $1,381 stockholders’ deficit, and continuing dependence on outside support.
- Verify whether the company obtained the proposed $50,000 working capital and $500,000 distribution financing, and whether the stated 2015 milestones were achieved.
- Check the operative Snotarator agreement, its correct expiration date, any extension, and the company’s actual product, sales, and distribution status.
- Assess ownership concentration, related-party arrangements, dilution risk, and any remediation of the disclosed control weaknesses.